

John G Kuruvilla

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5323376/john-g-kuruvilla-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

4,140
citations

23
h-index

64
g-index

118
ext. papers

5,053
ext. citations

4.2
avg, IF

5.18
L-index

#	Paper	IF	Citations
96	Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>EJHaem</i> , 2022 , 3, 139-153	0.9	1
95	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.. <i>Cancers</i> , 2022 , 14,	6.6	1
94	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pre-transplant Deauville score and residual metabolic tumor volume.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
93	Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.. <i>Leukemia and Lymphoma</i> , 2022 , 1-8	1.9	0
92	An evaluation of pembrolizumab for classical Hodgkin lymphoma.. <i>Expert Review of Hematology</i> , 2022 , 1-9	2.8	
91	Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. <i>EJHaem</i> , 2022 , 3, 223-227	0.9	
90	Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience. <i>Blood</i> , 2021 , 138, 2525-2525	2.2	
89	Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume. <i>Blood</i> , 2021 , 138, 1383-1383	2.2	
88	Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. <i>Blood</i> , 2021 , 138, 3574-3574	2.2	0
87	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2021 , 138, 3055-3055	2.2	0
86	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 ,	7.8	1
85	Evolving management strategies for lymphomas during the COVID-19 pandemic. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1046-1056	1.9	1
84	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021 , 22, 512-524	21.7	36
83	Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2400-2409	4.4	0
82	Pembrolizumab for relapsed or refractory Hodgkin lymphoma - Author@ reply. <i>Lancet Oncology</i> , 2021 , 22, e235	21.7	
81	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 195, 388-398	4.5	8
80	Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study. <i>Pilot and Feasibility Studies</i> , 2021 , 7, 36	1.9	3

79	Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2153-2160	1.9	1
78	Developing anti-CD19 antibody-based combinations in lymphoma. <i>Lancet Oncology</i> , 2020 , 21, 870-877	2.7	2
77	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e100-e111	14.6	32
76	Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. <i>Blood</i> , 2020 , 136, 12-12	2.2	4
75	Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. <i>F1000Research</i> , 2020 , 9,	3.6	4
74	Radiotherapy in mantle cell lymphoma: A literature review. <i>Hematological Oncology</i> , 2020 , 38, 223-228	1.3	0
73	Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 15-21	5.9	10
72	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020 , 4, 5762-5771	7.8	2
71	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3014-3017	1.9	1
70	Pembrolizumab for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1119-1126	5.4	10
69	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2576-2579	1.9	
68	A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin lymphoma weighing ≥ 70 kg. <i>Bone Marrow Transplantation</i> , 2019 , 54, 258-264	4.4	1
67	Significance of treatment response when managing patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 349-357	1.9	2
66	Optimal management of mantle cell lymphoma in the primary setting. <i>Expert Review of Hematology</i> , 2019 , 12, 715-721	2.8	
65	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 4095-4095	2.2	5
64	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 243-243	2.2	32
63	Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. <i>Blood</i> , 2019 , 134, 875-875	2.2	
62	The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival. <i>Blood</i> , 2019 , 134, 1559-1559	2.2	

61	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2027-2027	2.2	
60	A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study <i>Leukemia and Lymphoma</i> , 2019 , 60, 912-919	1.9	12
59	Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. <i>BMJ Open</i> , 2018 , 8, e017578	3	3
58	Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2018 , 53, 347-351	4.4	
57	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin lymphoma: an international, multicentre, single-arm, phase 1-2 trial. <i>Lancet Oncology</i> , 2018 , 19, 257-266	21.7	67
56	Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018 , 180, 757-760	4.5	10
55	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018 , 131, 182-190	2.2	92
54	Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study. <i>Blood</i> , 2018 , 132, 4843-4843	2.2	0
53	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1428-1439	2.2	377
52	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 942-950	2.2	175
51	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12. <i>Leukemia and Lymphoma</i> , 2017 , 58, 64-69	1.9	9
50	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <i>Annals of Hematology</i> , 2017 , 96, 805-813	2.2	8
49	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017 , 130, 267-270	2.2	201
48	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2017 , 129, 3175-3183	2.2	88
47	Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2607-2614	1.9	10
46	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. <i>Drugs</i> , 2017 , 77, 1645-1655	2.2	4
45	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017 , 130, 1800-1808	2.2	653
44	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1358-1365	1.9	23

43	Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1283-94	21.7	643
42	Gamma Delta T Cell Subset V Gamma 2+ Expansion Associated with Longterm Infliximab Treatment in a Patient with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016 , 43, 2079-2082	4.1	1
41	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3733-3739	2.2	486
40	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology, The</i> , 2016 , 17, 164-173	21.7	199
39	Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study. <i>Blood</i> , 2016 , 128, 1108-1108	2.2	23
38	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1110-1110	2.2	33
37	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016 , 128, 2923-2923	2.2	4
36	Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab Naïve Patients?. <i>Blood</i> , 2016 , 128, 1795-1795	2.2	
35	Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. <i>Blood</i> , 2016 , 128, 690-690	2.2	
34	A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation. <i>Blood</i> , 2016 , 128, 4227-4227	2.2	
33	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. <i>Blood</i> , 2016 , 128, 4645-4645	2.2	
32	Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2016 , 128, 3005-3005	2.2	0
31	Treatment Outcome of North American Patients with Adult T-Cell Leukemia/Lymphoma: Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2016 , 128, 3010-3010	2.2	
30	A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001. <i>Blood</i> , 2016 , 128, 1849-1849	2.2	
29	The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. <i>Blood</i> , 2016 , 127, 2093-100	2.2	22
28	Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 627-634.e5	2	6
27	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e73-81	2	10
26	A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 59-74	2	12

25	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. <i>Blood</i> , 2015 , 126, 733-8	2.2	26
24	Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 3289-3289	2.2	1
23	Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015 , 126, 3983-3983	2.2	3
22	Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2015 , 126, 3986-3986	2.2	13
21	Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience. <i>Blood</i> , 2015 , 126, 5057-5057	2.2	
20	Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. <i>Cancer Discovery</i> , 2014 , 4, 527-37	24.4	67
19	Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3490-6	2.2	251
18	Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1813-8	4.7	12
17	Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1751-7	4.7	13
16	Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 556-63	4.7	27
15	Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2502-7	1.9	25
14	Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease. <i>Clinical Transplantation</i> , 2013 , 27, 930-7	3.8	7
13	Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1164-71	2.2	80
12	Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. <i>Haematologica</i> , 2012 , 97, 751-7	6.6	21
11	Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 18-28	9.7	61
10	Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. <i>Blood</i> , 2012 , 120, 4184-4184	2.2	
9	How I treat relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2011 , 117, 4208-17	2.2	106
8	Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. <i>Haematologica</i> , 2010 , 95, 1496-502	6.6	14

7	Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study. <i>Blood</i> , 2010 , 116, 1763-1763	2.2	5
6	Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592). <i>Blood</i> , 2010 , 116, 284-284 ^{2.2}	2.2	6
5	Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma. <i>Blood</i> , 2010 , 116, 800-800	2.2	
4	Autologous Stem Cell Transplantation for Adolescents and Young Adults with Relapsed and Refractory Hodgkin Lymphoma. <i>Blood</i> , 2010 , 116, 2402-2402	2.2	1
3	Standard therapy of advanced Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 497-506	3.1	54
2	A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin@ lymphoma. <i>Hematology</i> , 2006 , 11, 25-9	2.2	17
1	Outcomes of Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B Cell Lymphoma (PMLCL) Are Inferior to Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2005 , 106, 2085-2085	2.2	1